In the heart of Switzerland's capital
More than 1,800 employees at the Bern facility develop and manufacture innovative biotherapies derived from human plasma. Thanks to these products, people with life-threatening diseases may lead a normal life. In the heart of the city of Bern, CSL Behring looks back on a long and successful history in the immunoglobulin market. Continuous innovation combined with the highest demands on quality and the use of cutting-edge technology have made us a global leader in the field of immunotherapy. Our major markets are the USA, Europe, Japan, China, Latin America, and the Middle East.. CSL Behring AG’s products are sold around the world.
The Bern products
for the treatment of immunodeficiencies and functional disorders of the immune system
- Specific immunoglobulin
to prevent haemolytic disease of newborns
for emergency treatments and critical care